Go Pro
NASDAQ:SRTS

Sensus Healthcare (SRTS) Stock Price, News & Analysis

Sensus Healthcare logo
$3.34 +0.05 (+1.55%)
As of 11:10 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Sensus Healthcare Stock (NASDAQ:SRTS)

Advanced

Key Stats

Today's Range
$3.16
$3.38
50-Day Range
$2.74
$3.49
52-Week Range
$2.66
$5.49
Volume
13,697 shs
Average Volume
64,748 shs
Market Capitalization
$55.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83
Consensus Rating
Moderate Buy

Company Overview

Sensus Healthcare, Inc. is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls. These systems allow dermatologists and radiation oncologists to administer precise doses of radiation directly to lesions while sparing surrounding healthy tissue. In addition to its hardware, Sensus Healthcare offers training, credentialing support and treatment planning assistance, helping clinics and hospitals integrate SRT into their service offerings and meet regulatory requirements.

Founded in 2004 and headquartered in Jacksonville, Florida, Sensus Healthcare has built a network of clinical partners and distributors across the United States and select international markets. The company’s sales and service organization works closely with dermatology practices, oncology centers and academic institutions to facilitate device installation, maintenance and ongoing technical support. Over time, Sensus Healthcare has expanded its outreach through strategic collaborations with key opinion leaders and specialty societies to raise awareness of superficial radiation therapy protocols and best practices.

Under the leadership of President and CEO R. Scott Ruskin, Sensus Healthcare continues to pursue research and development initiatives aimed at broadening the clinical applications of its SRT technology. The company remains focused on generating long-term data on treatment efficacy and patient outcomes, while exploring opportunities to enhance device capabilities and workflow integration. With a growing installed base and a commitment to education and clinical validation, Sensus Healthcare positions itself as a dedicated provider of non-invasive radiation therapy solutions for dermatology and oncology practitioners.

AI Generated. May Contain Errors.

Sensus Healthcare Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

SRTS MarketRank™: 

Sensus Healthcare scored higher than 69% of companies evaluated by MarketBeat, and ranked 250th out of 918 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sensus Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Sensus Healthcare has a consensus price target of $5.83, representing about 74.6% upside from its current price of $3.34.

  • Amount of Analyst Coverage

    Sensus Healthcare has only been the subject of 3 research reports in the past 90 days.

  • Read more about Sensus Healthcare's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sensus Healthcare is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sensus Healthcare is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sensus Healthcare has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sensus Healthcare's valuation and earnings.
  • Percentage of Shares Shorted

    1.42% of the float of Sensus Healthcare has been sold short.
  • Short Interest Ratio / Days to Cover

    Sensus Healthcare has a short interest ratio ("days to cover") of 8.82.
  • Change versus previous month

    Short interest in Sensus Healthcare has recently increased by 1.61%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sensus Healthcare does not currently pay a dividend.

  • Dividend Growth

    Sensus Healthcare does not have a long track record of dividend growth.

  • News Sentiment

    Sensus Healthcare has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Sensus Healthcare this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for SRTS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Sensus Healthcare to their MarketBeat watchlist in the last 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $112,765.00 in company stock, which represents 0.2050% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Sensus Healthcare insiders have bought more of their company's stock than they have sold. Specifically, they have bought $112,765.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.20% of the stock of Sensus Healthcare is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    25.30% of the stock of Sensus Healthcare is held by institutions.

  • Read more about Sensus Healthcare's insider trading history.
Receive SRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensus Healthcare and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SRTS Stock News Headlines

Sensus (SRTS) Q2 2026 Earnings Call Transcript
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
See More Headlines

SRTS Stock Analysis - Frequently Asked Questions

Sensus Healthcare's stock was trading at $3.98 at the beginning of the year. Since then, SRTS shares have decreased by 16.1% and is now trading at $3.3410.

Sensus Healthcare, Inc. (NASDAQ:SRTS) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.41. The company earned $2.29 million during the quarter, compared to analysts' expectations of $4.60 million. Sensus Healthcare had a negative trailing twelve-month return on equity of 21.57% and a negative net margin of 88.45%.
Read the conference call transcript
.

Sensus Healthcare (SRTS) raised $20 million in an initial public offering (IPO) on Wednesday, March 30th 2016. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company acted as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

Top institutional shareholders of Sensus Healthcare include Bank of New York Mellon Corp (0.61%), BlackRock Inc. (0.51%) and EP Wealth Advisors LLC (0.10%). Insiders that own company stock include Joseph C Sardano, Eric Sachetta, Michael Sardano and John Heinrich.
View institutional ownership trends
.

Shares of SRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sensus Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD), EMCOR Group (EME), e.l.f. Beauty (ELF) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/13/2026
Today
8/27/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:SRTS
CIK
1494891
Employees
40
Year Founded
2010

Price Target and Rating

High Price Target
$7.50
Low Price Target
$4.00
Potential Upside/Downside
+74.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.72 million
Net Margins
-88.45%
Pretax Margin
-72.53%
Return on Equity
-21.57%
Return on Assets
-19.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.71
Quick Ratio
4.30

Sales & Book Value

Annual Sales
$17.51 million
Price / Sales
3.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.24 per share
Price / Book
1.49

Miscellaneous

Outstanding Shares
16,462,000
Free Float
14,783,000
Market Cap
$55.00 million
Optionable
Optionable
Beta
1.10

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:SRTS) was last updated on 8/27/2026 by MarketBeat.com Staff.
From Our Partners